NASDAQ:ONCS - OncoSec Medical Stock Price, Forecast & News

OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."

OncoSec Medical shares reverse split before market open on Tuesday, May 21st 2019. The 1-10 reverse split was announced on Monday, May 20th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 20th 2019. An investor that had 100 shares of OncoSec Medical stock prior to the reverse split would have 10 shares after the split.

OncoSec Medical Inc (NASDAQ:ONCS) issued its quarterly earnings data on Wednesday, October, 25th. The biotechnology company reported ($2.80) earnings per share for the quarter, missing the consensus estimate of ($2.30) by $0.50. View OncoSec Medical's Earnings History.

1 analysts have issued twelve-month price objectives for OncoSec Medical's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate OncoSec Medical's share price to reach $6.00 in the next year. This suggests a possible upside of 197.0% from the stock's current price. View Analyst Price Targets for OncoSec Medical.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.

Media stories about ONCS stock have trended negative this week, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OncoSec Medical earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for OncoSec Medical.

OncoSec Medical saw a decrease in short interest during the month of November. As of November 29th, there was short interest totalling 324,000 shares, a decrease of 9.8% from the November 14th total of 359,200 shares. Based on an average daily trading volume, of 264,300 shares, the days-to-cover ratio is currently 1.2 days. Currently, 3.6% of the company's shares are short sold. View OncoSec Medical's Current Options Chain.

Some companies that are related to OncoSec Medical include Paratek Pharmaceuticals (PRTK), CELYAD SA/ADR (CYAD), Strongbridge Biopharma (SBBP), Marinus Pharmaceuticals (MRNS), Helix Biopharma (HBPCF), Aduro BioTech (ADRO), PhaseBio Pharmaceuticals (PHAS), TFF Pharmaceuticals (TFFP), OASMIA PHARMACE/ADR (OASM), Synlogic (SYBX), Oramed Pharmaceuticals (ORMP), Immunic (IMUX), ESSA Pharma (EPIX), Inflarx (IFRX) and Millendo Therapeutics (MLND).

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoSec Medical investors own include Cytokinetics (CYTK), XOMA (XOMA), Inovio Pharmaceuticals (INO), Walt Disney (DIS), Anavex Life Sciences (AVXL), Rexahn Pharmaceuticals (REXN), Idera Pharmaceuticals (IDRA), Arena Pharmaceuticals (ARNA), Catalyst Pharmaceuticals (CPRX) and Synergy Pharmaceuticals (SGYP).

OncoSec Medical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include D.A. Davidson & CO. (0.22%) and Salzhauer Michael (0.13%). Company insiders that own OncoSec Medical stock include Alpha Holdings, Inc, Avtar S Dhillon, Daniel J O'connor, James M Demesa, Punit Dhillon, Richard B Slansky and Sara Bonstein. View Institutional Ownership Trends for OncoSec Medical.

ONCS stock was bought by a variety of institutional investors in the last quarter, including D.A. Davidson & CO. and Salzhauer Michael. Company insiders that have bought OncoSec Medical stock in the last two years include Alpha Holdings, Inc, Daniel J O'connor, James M Demesa and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.

Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONCS stock can currently be purchased for approximately $2.02.

OncoSec Medical has a market capitalization of $21.59 million. OncoSec Medical employs 33 workers across the globe.View Additional Information About OncoSec Medical.

The official website for OncoSec Medical is http://www.oncosec.com/.

OncoSec Medical's mailing address is 3565 GENERAL ATOMICS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]